| Assay ID | Title | Year | Journal | Article |
|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID671335 | Inhibition of Aur B | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID747736 | Inhibition of human MPS1 expressed in Escherichia coli | 2013 | Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
| Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125). |
| AID670210 | Antitumor activity against human HCT116 xenografted in mouse assessed as tumor growth inhibition at 150 mg/kg, ip administered one dose every 4 days 6 times | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID671337 | Kinetic solubility of the compound at pH 7.4 | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID670208 | Oral bioavailability in CD-1 mouse at 10 mg/kg | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID671332 | Cytotoxicity against human HCT116 cells | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID671331 | Inhibition of Mps1 | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID1552040 | Inhibition of MPS1 (519 to 808 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) after 18 hrs | 2019 | European journal of medicinal chemistry, Aug-01, Volume: 175 | Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective. |
| AID671333 | Cell cycle arrest in human HCT116 cells assessed as G2 checkpoint inhibition by Hoescht 33342 staining method | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID1057802 | Inhibition of full-length Mps1 kinase (unknown origin) | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
| Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads. |
| AID1184501 | Inhibition of GST-fused full length human TTK compound pre-incubated for 15 mins prior ATP addition by MBP-based assay | 2014 | Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
| Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides. |
| AID1057801 | Cytotoxicity against human HCT116 cells | 2013 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24
| Novel Mps1 kinase inhibitors: from purine to pyrrolopyrimidine and quinazoline leads. |
| AID1203305 | Antitumor activity against human HCT116 cells xenografted in nude mouse assessed as tumor growth inhibition at 30 mg/kg, po qd administered for 21 days measured on day 22 relative to vehicle-treated control | 2015 | Journal of medicinal chemistry, Apr-23, Volume: 58, Issue:8
| The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents. |
| AID671334 | Inhibition of Aur A | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID747739 | Antiproliferative activity against human A549 cells after 72 hrs by WST8 assay | 2013 | Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
| Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125). |
| AID670209 | Antitumor activity against human HCT116 xenografted in mouse assessed as tumor growth inhibition at 150 mg/kg, ip administered one dose everyday 15 times | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID671336 | Inhibition of PLK1 | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID671338 | Apparent permeability of the compound by PAMPA | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID671339 | Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 40 mins by mass spectrometry | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors. |
| AID1345801 | Human TTK protein kinase (TTK family) | 2011 | Molecular cancer therapeutics, Dec, Volume: 10, Issue:12
| Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |